Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 205-215

  Al Asmari, Abdulrahman K ^a   Ullah, Zabih ^a   Tariq, Mohammad ^a   Fatani, Amal ^b  

^a The General Directorate of Armed Forces Health Services   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Bioavailability; Blood brain barrier; Donepezil; Intranasal; Liposomes

Indexed keywords

DONEPEZIL; LIPOSOME; 1,2-DISTEAROYLLECITHIN; CHOLESTEROL; DELAYED RELEASE FORMULATION; DRUG CARRIER; INDAN DERIVATIVE; MACROGOL DERIVATIVE; NOOTROPIC AGENT; PHOSPHATIDYLCHOLINE; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; ENCAPSULATION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; RAT; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; BRAIN; CHEMISTRY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; INTRANASAL DRUG ADMINISTRATION; MALE; MEDICINAL CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; TISSUE DISTRIBUTION; WISTAR RAT;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BRAIN; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; INDANS; LIPOSOMES; MALE; NOOTROPIC AGENTS; PARTICLE SIZE; PHOSPHATIDYLCHOLINES; PIPERIDINES; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; TISSUE DISTRIBUTION;

EID: 84955139262     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S93937     Document Type: Article

References (46)

1. Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden of mental, neurological and substance use disorders: an analysis from the global burden of disease study 2010. PLoS One. 2015;10:e0116820.
2. Girardin F. Membrane transporter proteins: a challenge for CNS drug development. Dialogues Clin Neurosci. 2006;8(3):311–321.
3. Matsumoto J, Takata F, Machida T, et al. Tumor necrosis factor-α-stimulated brain pericytes possess a unique cytokine and chemokine release profile and enhance microglial activation. Neurosci Lett. 2014;578:133–138.
4. Upadhyay RK. Drug delivery systems, CNS protection, and the blood brain barrier. Biomed Res Int. 2014;2014:869269.
5. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int J Pharm. 2005;298(2):274–292.
6. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain. CNS Drugs. 2009;23(1):35–58.
7. Chen H, Chen CC, Acosta C, Wu SY, Sun T, Konofagou EE. A new brain drug delivery strategy: focused ultrasound-enhanced intranasal drug delivery. PLoS One. 2014;9(10):e108880.
8. Miyake MM, Bleier BS. The blood-brain barrier and nasal drug delivery to the central nervous system. Am J Rhinol Allergy. 2015;29(2):124–127.
9. Sousa F, Castro P, Fonte P, Sarmento B. How to overcome the limitations of current insulin administration with new non-invasive delivery systems. Ther Deliv. 2015;6(1):83–94.
10. Klossek JM. Efficacy and safety of mometasone furoate nasal spray in the treatment of sinusitis or acute rhinosinusitis. Rev Laryngol Otol Rhinol (Bord). 2007;128(3):187–192.
11. Vyas TK, Shahiwala A, Marathe S, Misra A. Intranasal drug delivery for brain targeting. Curr Drug Deliv. 2005;2(2):165–175.
12. Chen J, Jiang H, Wu Y, Li Y, Gao Y. A novel glycyrrhetinic acid-modified oxaliplatin liposome for liver-targeting and in vitro/vivo evaluation. Drug Des Devel Ther. 2015;9:2265–2275.
13. Spuch C, Navarro C. Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer’s disease and Parkinson’s disease). J Drug Deliv. 2011;2011:469679.
14. Law SL, Huang KJ, Chou HY. Preparation of desmopressin-containing liposomes for intranasal delivery. J Control Release. 2001;70(3):375–382.
15. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv. 2007;4(4):297–305.
16. Arumugam K, Subramanian G, Mallayasamy S, Averineni R, Reddy M, Udupa N. A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm. 2008;58(3):287–297.
17. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm. 2009;379(1):146–157.
18. Hamblin KA, Wong JP, Blanchard JD, Atkins HS. The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy. Front Cell Infect Microbiol. 2014;4:79.
19. Ali J, Ali M, Baboota S, et al. Potential of nanoparticulate drug delivery systems by intranasal administration. Curr Pharm Des. 2010;16(14):1644–1653.
20. Zeng S, Ye M, Qiu J, et al. Preparation and characterization of genipin-cross-linked silk fibroin/chitosan sustained-release microspheres. Drug Des Devel Ther. 2015;9:2501–2514.
21. Zaki NM, Awad GA, Mortada ND, ElHady SSA. Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. Eur J Pharm Sci. 2007;32(4):296–307.
22. Al-Asmari AK, Ullah Z, Al-Sabaan F, Tariq M, Al-Eid A, Al-Omani SF. Effect of vitamin D on bioavailability and lipid lowering efficacy of simvastatin. Eur J Drug Metab Pharmacokinet. 2015;40(1):87–94.
23. Wang X, Guan Q, Chen W, Hu X, Li L. Novel nanoliposomal delivery system for polydatin: preparation, characterization, and in vivo evaluation. Drug Des Devel Ther. 2015;9:1805–1813.
24. Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol. 2004;56(1):3–17.
25. Misra A, Ganesh S, Shahiwala A, Shah SP. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci. 2003;6(2):252–273.
26. Song JM, Kirtane AR, Upadhyaya P, et al. Intranasal delivery of liposomal indole-3-carbinol improves its pulmonary bioavailability. Int J Pharm. 2014;477(1–2):96–101.
27. Corace G, Angeloni C, Malaguti M, et al. Multifunctional liposomes for nasal delivery of the anti-Alzheimer drug tacrine hydrochloride. J Liposome Res. 2014;24(4):323–335.
28. van den Berg MP, Verhoef JC, Romeijn SG, Merkus FW. Uptake of estradiol or progesterone into the CSF following intranasal and intravenous delivery in rats. Eur J Pharm Biopharm. 2004;58(1):131–135.
29. Haeri A, Alinaghian B, Daeihamed M, Dadashzadeh S. Preparation and characterization of stable nanoliposomal formulation of fluoxetine as a potential adjuvant therapy for drug-resistant tumors. Iran J Pharm Res. 2014;13(Suppl):3–14.
30. Bhujbal SV, de Vos P, Niclou SP. Drug and cell encapsulation: alternative delivery options for the treatment of malignant brain tumors. Adv Drug Deliv Rev. 2014;67–68:142–153.
31. Ungaro F, d’Angelo I, Coletta C, et al. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release. 2012;157(1):149–159.
32. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. Physico-chemical stability of colloidal lipid particles. Biomaterials. 2003;24(23):4283–4300.
33. Catalin Balaure P, Mihai Grumezescu A. Smart synthetic polymer nanocarriers for controlled and site-specific drug delivery. Curr Top Med Chem. 2015;15(15):1424–1490.
34. Nagayasu A, Uchiyama K, Kiwada H. The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Deliv Rev. 1999;40(1):75–87.
35. Furubayashi T, Kamaguchi A, Kawaharada K, et al. Evaluation of the contribution of the nasal cavity and gastrointestinal tract to drug absorption following nasal application to rats. Biol Pharm Bull. 2007;30(3):608–611.
36. Varshosaz J, Sadrai H, Heidari A. Nasal delivery of insulin using bioadhesive chitosan gels. Drug Delivery. 2006;13(1):31–38.
37. Ikechukwu Ugwoke M, Kaufmann G, Verbeke N, Kinget R. Intranasal bioavailability of apomorphine from carboxymethylcellulose-based drug delivery systems. Int J Pharm. 2000;202(1–2):125–131.
38. Graff CL, Pollack GM. Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci. 2005;94(6):1187–1195.
39. Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010;99(4):1654–1673.
40. Hashizume R, Ozawa T, Gryaznov SM, et al. New therapeutic approach for brain tumors: intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol. 2008;10(2):112–120.
41. Jogani VV, Shah PJ, Mishra P, Mishra AK, Misra AR. Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis Assoc Disord. 2008;22(2):116–124.
42. Jogani VV, Shah PJ, Mishra P, Mishra AK, Misra AR. Nose-to-brain delivery of tacrine. J Pharm Pharmacol. 2007;59(9):1199–1205.
43. Doyle KP, Yang T, Lessov NS, et al. Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke. J Cereb Blood Flow Metab. 2008;28(6):1235–1248.
44. Martin-Banderas L, Holgado MA, Venero JL, Alvarez-Fuentes J, Fernandez-Arevalo M. Nanostructures for drug delivery to the brain. Curr Med Chem. 2011;18(34):5303–5321.
45. Jain KK. Nanobiotechnology-based strategies for crossing the blood-brain barrier. Nanomedicine (Lond). 2012;7(8):1225–1233.
46. Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA. Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv. 2008;5(2):155–174.